The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology

May 9, 2022

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

APHINITY | Journal of the National Cancer Institute (JNCI)

May 5, 2022

Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

APHINITY | AACR Cancer Research

Feb 15, 2022

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

The ALTTO Trial: Updated Results from the international phase III ALTTO trial (BIG2-06/Alliance N063D)

May 1, 2021

Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.

The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up

May 1, 2021

The JCO confirms the invasive disease-free survival benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early breast cancer.

A pooled analysis of the Cardiac Events in three adjuvant trials: HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials)

Jan 1, 2020

Breast Cancer Research and Treatment published that Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Further research is needed to individualize prevention and management of trastuzumab-associated cardiotoxicity.

The APHINITY Trial: Results of the Primary Analysis

Jul 13, 2017

An article published in the New England Journal of Medicine (NEJM) reports that pertuzumab, when added to chemotherapy and trastuzumab, significantly improved the rates of invasive-disease–free survival among patients with HER2-positive early breast cancer.

The HERA Trial: Final Analysis Results

Feb 16, 2017

An article published in The Lancet shares the results from the final analysis of the HERceptin Adjuvant (HERA) trial.

The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

Jul 1, 2016

JAMA Internal Medicine reports on the investigation into participation rates, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries.